YWYandong Wen

Yandong Wen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yandong Wen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • B-H Zhang

    China Acad Chinese Med Sci, Xiyuan Hosp, Dept Gastroenterol, Beijing, Peoples R China

    1 shared publication
  • Bochao Yuan

    Department of Chinese Medicine, Eye Hospital, China Academy of Chinese Medical Sciences

    1 shared publication
  • H. Xue

    China Acad Chinese Med Sci, Xiyuan Hosp, Dept Gastroenterol, Beijing, Peoples R China

    1 shared publication
  • J. Ke

    Department of Gastroenterology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

    1 shared publication
  • Li Zhongyu

    China Acad Chinese Med Sci, Inst Digest Dis, Xiyuan Hosp, Beijing 100091, Peoples R China

    1 shared publication
  • M. Zhong

    China Acad Chinese Med Sci, Xiyuan Hosp, Dept Gastroenterol, Beijing, Peoples R China

    1 shared publication

Latest Publications

  • Open Access

    From inflammation to carcinogenesis: MiRNA regulates epithelial-mesenchymal transition to facilitate malignant progression of gastric precancerous lesions

    by Yibing Tian, Tai Zhang, Bochao Yuan, Zhongyu Li, Ting Chen, Yandong Wen

    The process of chronic gastritis transforming into gastric cancer (GC) follows the classic Correa cascade, with persistent inflammation driving the stepwise transition from normal gastric mucosa through superficial gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately carcinoma. Among these stages, intestinal metaplasia and dysplasia occurring on an atrophic mucosal background are widely regarded as the most common gastric precancerous lesions (GPL) because of their pronounced carcinogenic risk. Chronic inflammation can induce epithelial–mesenchymal transition (EMT), thereby accelerating gastric malignant progression. In the GPL stage, the inflammatory gastric microenvironment commonly induces partial EMT (pEMT); importantly, this state is partly reversible and may be amenable to intervention to slow disease progression. As lesions advance, epithelial cells more fully undergo EMT, acquiring greater motility, invasiveness, and metastatic capability, which increases susceptibility to malignant conversion. MicroRNAs (miRNAs) are key molecular regulators in the transition from chronic gastritis to GC through EMT modulation. This review comprehensively discusses inflammation-driven EMT activation and functionally classifies pro-EMT oncomiRNAs (e.g., miR-21, miR-155) and anti-EMT tumor-suppressive miRNAs (e.g., miR-200 family, let-7 family, miR-34a), delineating a complex crosstalk network among inflammation, miRNA, and EMT. We further evaluate miRNAs as non-invasive biomarkers for early detection and prognosis of GPL and discuss emerging therapeutic strategies targeting the miRNA–EMT axis, including nanoparticle- or exosome-based delivery systems, miRNA antagonists, and miRNA sponges. Nevertheless, clinical application of circulating miRNAs remains limited by insufficient assay standardization and validation, incomplete target specificity, off-target effects, suboptimal delivery efficiency, and a lack of large-scale clinical evidence. By integrating molecular mechanisms and transformation status of miRNA-EMT axis in GPL, this review provides new insights for precision prevention and targeted intervention in gastric carcinogenesis.


  • Therapeutic mechanisms of integrated traditional Chinese and conventional medicine underlying its treatment of precancerous lesions of gastric cancer

    by Xu Qing, Wang Yang, Li Zhongyu, Yan Jiaxing, Zhao Yingpan, Wang Ping, Wen Yandong

    China has a high incidence of gastric cancer. Secondary prevention of gastric cancer is a major public health problem that must be solved urgently. Modern medicine focuses on the pathogenesis of precancerous lesions of gastric cancer (PLGC), and it has been found that there are a variety of abnormal gene expression patterns in PLGC. This study summarizes recent advances in our understanding of the therapeutic mechanisms of PLGC from various clinical studies; this will provide a reference for studying the therapeutic mechanisms of Traditional Chinese Medicine in the treatment of PLGC from the combined points of view of Traditional Chinese and Conventional medicine.


  • MiR-1-3p suppresses cell proliferation and invasion and targets STC2 in gastric cancer

    by J. Ke, B-H Zhang, Y-Y Li, M. Zhong, W. Ma, H. Xue, Y-D Wen, Y-D Cai

    OBJECTIVE: MiR-1 has been reported to act as an inhibitory microRNA in gastric cancer (GC). This study aimed to investigate the regulatory mechanism by which miR-1-3p blocks the progression of GC by targeting stanniocalcin 2 (STC2). PATIENTS AND METHODS: The expression level of miR-1-3p in GC was assessed via quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Expressions of STC2 were measured by qRT-PCR and Western blot analysis. Proliferation and invasion assays were detected by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and transwell assays. respectively. Moreover, the dual-luciferase reporter assay was used to confirm the binding sites between miR-1-3p and STC2. RESULTS: MiR-1-3p was significantly down-regulated in GC. Moreover. abnormal expression of miR-1-3p was correlated with GC tumor size. Functionally, overexpression of miR-1-3p inhibited proliferation and invasion in GC by inhibiting stanniocalcin 2 (STC2) expressions. In contrast. STC2 was significantly up-regulated in GC. Furthermore, miR-1-3p negatively regulated STC2 expression in GC. The upregulation of STC2 weakened the inhibitory effect of miR-1-3p in GC. CONCLUSIONS: MiR-1-3p suppressed cell proliferation and invasion by targeting STC2 in GC. providing a novel therapeutic target for GC.